Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo

Ma,Pan; He,Qiang; Li,Wei; Li,Xianliang; Han,Huamin; Jin,Mengmeng; Liu,Changzhen; Tao,Hua; Ma,Juan; Gao,Bin

doi:10.3892/or.2015.4233

Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo

Authors:
- Pan Ma
- Qiang He
- Wei Li
- Xianliang Li
- Huamin Han
- Mengmeng Jin
- Changzhen Liu
- Hua Tao
- Juan Ma
- Bin Gao
View Affiliations

Affiliations: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, P.R. China, The Beijing Chao-Yang Hospital Capital Medical University, Beijing 100020, P.R. China, The General Hospital of Chinese People's Liberation Army, Beijing 100853, P.R. China
Published online on: August 28, 2015 https://doi.org/10.3892/or.2015.4233
Pages: 2567-2575

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epidermal growth factor receptor (EGFR) is an attractive target for the immunotherapy of EGFR+ tumors. Adjuvant immunotherapy with cytokine-induced killer (CIK) cells may improve progression-free survival rates in patients suffering from cancer. In the present study, we examined the bispecific antibody anti-CD3 x anti-EGFR (EGFRBi-Ab) for its ability to redirect CIK cells to target EGFR-positive glioblastoma. The specific cytolytic activity of CIK cells armed with EGFRBi-Ab against U87MG-luc cells was evaluated by bioluminescent signal generated using luciferase reporter assay which did not alter the surface molecule expression or proliferation ability of U87MG cells. In contrast to unarmed CIK cells, increased cytotoxic activity of EGFRBi-armed CIK cells against the U87MG-luc target was observed at effector/target (E/T) ratios of 5:1, 10:1, and 20:1. Moreover, EGFRBi-armed CIK cells secreted significantly higher levels of IFN-γ, TNF-α, and IL-2 than their unarmed CIK counterpart cells. Furthermore, in glioblastoma xenograft mice, infusion of the EGFRBi-armed CIK cells successfully inhibited the growth of glioblastoma tumors. The in vitro and in vivo antitumor effects of EGFRBi-armed CIK cells support their clinical use for treatment of glioblastoma in the future.

View Figures

View References

1	Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL: Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
2	Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
3	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
4	Agrawal NS, Miller R Jr, Lal R, Mahanti H, Dixon-Mah YN, DeCandio ML, Vandergrift WA III, Varma AK, Patel SJ, Banik NL, et al: Current studies of immunotherapy on glioblastoma. J Neurol Neurosurg. 1:210001042014.PubMed/NCBI
5	Bonavia R, Inda MM, Cavenee WK and Furnari FB: Heterogeneity maintenance in glioblastoma: A social network. Cancer Res. 71:4055–4060. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gyorki DE, Spillane J, Speakman D, Shackleton M and Henderson MA: Current management of advanced melanoma: A transformed landscape. ANZ J Surg. 84:612–617. 2014. View Article : Google Scholar : PubMed/NCBI
7	Escudier B and Albiges L: Pazopanib for the treatment of advanced renal cell cancer. Expert Opin Orphan Drugs. 2:605–616. 2014. View Article : Google Scholar
8	Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, et al: Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. Curr Drug Targets. 11:790–800. 2010. View Article : Google Scholar : PubMed/NCBI
9	Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, et al: Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 20:1596–1603. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hishii M, Nitta T, Ebato M, Okumura K and Sato K: Targeting therapy for glioma by LAK cells coupled with bispecific antibodies. J Clin Neurosci. 1:261–265. 1994. View Article : Google Scholar : PubMed/NCBI
11	Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL and Grimm EA: Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res. 8:81–87. 1986.PubMed/NCBI
12	Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C and Chico S: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 27:398–404. 2004. View Article : Google Scholar : PubMed/NCBI
13	Pfosser A, Brandl M, Salih H, Grosse-Hovest L and Jung G: Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A pre-clinical study. Int J Cancer. 80:612–616. 1999. View Article : Google Scholar : PubMed/NCBI
14	Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME and Parsa AT: CD8⁺ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 17:1381–1385. 2010. View Article : Google Scholar : PubMed/NCBI
15	Waziri A, Killory B, Ogden AT III, Canoll P, Anderson RC, Kent SC, Anderson DE and Bruce JN: Preferential in situ CD4⁺CD56⁺ T cell activation and expansion within human glioblastoma. J Immunol. 180:7673–7680. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK and Lum LG: Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 59:1198–1205. 2012. View Article : Google Scholar : PubMed/NCBI
17	Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CW, Clezardin P and van der Pluijm G: Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis. 24:699–705. 2007. View Article : Google Scholar : PubMed/NCBI
18	Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar
19	Han H, Liu Q, He W, Ong K, Liu X and Gao B: An efficient vector system to modify cells genetically. PLoS One. 6:e263802011. View Article : Google Scholar : PubMed/NCBI
20	Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
21	Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, et al: Bispecific anti-CD3xanti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol. 45:2446–2454. 2014.PubMed/NCBI
22	Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, et al: HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One. 8:e732612013. View Article : Google Scholar : PubMed/NCBI
23	Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N and Zhang X: A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 5:e118672010. View Article : Google Scholar : PubMed/NCBI
24	Padfield E, Ellis HP and Kurian KM: Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 5:52015. View Article : Google Scholar : PubMed/NCBI
25	Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY and Lum LG: Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 12:183–190. 2006. View Article : Google Scholar : PubMed/NCBI
26	Jäkel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014:8972142014. View Article : Google Scholar : PubMed/NCBI
27	Badr CE and Tannous BA: Bioluminescence imaging: Progress and applications. Trends Biotechnol. 29:624–633. 2011. View Article : Google Scholar : PubMed/NCBI
28	Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A and Maekawa T: Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 217:243–253. 2005. View Article : Google Scholar
29	Tiffen JC, Bailey CG, Ng C, Rasko JE and Holst J: Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer. 9:2992010. View Article : Google Scholar : PubMed/NCBI
30	Patel MA, Kim JE, Ruzevick J, Li G and Lim M: The future of glioblastoma therapy: Synergism of standard of care and immunotherapy. Cancers (Basel). 6:1953–1985. 2014. View Article : Google Scholar
31	Keeren K, Friedrich M, Gebuhr I, Philipp S, Sabat R, Sterry W, Brandt C, Meisel C, Grütz G, Volk HD, et al: Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol. 183:4077–4087. 2009. View Article : Google Scholar : PubMed/NCBI
32	Swaika A, Hammond WA and Joseph RW: Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. Mar 4–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
33	Suzuki M and Cheung NK: Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 19:349–362. 2015. View Article : Google Scholar : PubMed/NCBI
34	Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH and Souweidane MM: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 111:257–264. 2013. View Article : Google Scholar